KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Lorundrostat in Participants With Uncontrolled Hypertension and Treatment-Resistant Hypertension: The Launch-HTN Randomized Clinical Trial.

Manish Saxena, Luke Laffin, Claudio Borghi, Beatriz Fernandez Fernandez, Jalal K Ghali, Branko Kopjar, Krishna Polu, Simon D Roger, B T Slingsby, Frank Strutz, Liffert Vogt, Matthew R Weir, David Rodman, Launch-HTN Investigators

JAMA 334(5) 409-418

PMID40587141
PMCIDPMC12210145
DOI10.1001/jama.2025.9413
发表日期2025-06-30
入排依据:未发现恶性肿瘤人群证据。
已检查 3 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 flow diagram;Figure 2:AI 判定为 other;Figure 3:森林图/亚组分析图。
摘要

摘要

IMPORTANCE: Uncontrolled hypertension remains a global health concern and dysregulated aldosterone production is a central mechanism. Lorundrostat, a novel aldosterone synthase inhibitor that reduces aldosterone production, demonstrated efficacy in participants with uncontrolled hypertension, including those with treatment-resistant hypertension. OBJECTIVE: To evaluate the efficacy and safety of lorundrostat for lowering blood pressure (BP) when added to a prescribed regimen of 2 to 5 antihypertensive medications in adults with uncontrolled hypertension and treatment-resistant hypertension. DESIGN, SETTING, AND PARTICIPANTS: In this phase 3, randomized clinical trial, adults with uncontrolled hypertension, including those with treatment-resistant hypertension, were enrolled between November 2023 and September 2024 at 159 clinic sites across 13 countries. The last date of follow-up was January 24, 2025. INTERVENTION: Randomization ratio of 1:2:1 to 50 mg/d of lorundrostat for 6 weeks followed by 100 mg/d of lorundrostat for 6 weeks (n = 270) if they met prespecified criteria, 50 mg/d of lorundrostat for 12 weeks (n = 541), or daily placebo for 12 weeks (n = 272). The prespecified criteria included systolic BP of 130 mm Hg or greater, potassium level of 4.8 mmol/L or less, sodium level of 135 mmol/L or greater, an estimated glomerular filtration rate (eGFR) of greater than 45 mL/min/1.73 m2, and less than a 25% reduction in eGFR. MAIN OUTCOME AND MEASURES: The primary outcome was change in automated office systolic BP at week 6 for participants randomized to 50 mg of lorundrostat vs placebo. Adverse events of special interest included dose reduction, interruption, or discontinuation due to events such as hyperkalemia, hyponatremia, and reduction in kidney function. RESULTS: Of the 1083 participants, the mean age was 61.6 years (SD, 10.3 years), 508 (46.9%) were female, 311 (28.7%) were Black or African American, 733 (67.7%) were White, and 685 (63.3%) had a body mass index of 30 or greater (obesity). At randomization, 432 participants (39.9%) were taking 2 prescribed antihypertensive medications and 651 (60.1%) were taking 3 or more. For the pooled 50 mg of lorundrostat group (n = 808), the least-squares mean change in automated office systolic BP at week 6 was -16.9 mm Hg (95% CI, -19.0 to -14.9 mm Hg) vs -7.9 mm Hg (95% CI, -11.5 to -4.2 mm Hg) for the placebo group (least-squares mean difference, -9.1 mm Hg [95% CI, -13.3 to -4.9 mm Hg]; P < .001). Hyponatremia, hyperkalemia, and reduction in kidney function were reported more often with lorundrostat vs placebo. In the 50 mg of lorundrostat group with possible escalation to 100 mg, treatment discontinuation occurred in 1 participant (0.37%) due to hyperkalemia, in 1 (0.37%) due to hyponatremia, and in 0 due to reduction in kidney function. In the 50 mg of lorundrostat group, treatment discontinuation occurred in 2 participants (0.37%) due to hyperkalemia, in 2 (0.37%) due to hyponatremia, and in 3 (0.56%) due to reduction in kidney function. Treatment-emergent adverse events occurred in 49.9% of participants (538/1078) and were mostly mild or moderate in severity. CONCLUSIONS AND RELEVANCE: The efficacy and safety of lorundrostat, an aldosterone synthase inhibitor, was demonstrated for lowering BP in adults with uncontrolled hypertension, including those with treatment-resistant hypertension. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT06153693.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1.. Flow of Participants Through the Launch-HTN Trial a The most frequent reasons were current use of treatment (or anticipated treatment) with any of the prohibited medications described in the trial protocol within a specified time frame (n = 15); had a condition that would preclude participation in the study (based on the opinion of the investigator) (n = 14); and had current, known, or presumed orthostatic hypotension (n = 9). b Participants were escalated to 100 mg of lorundrostat once daily after week 6 if all the following prespecified criteria were met at week 6: had an automated office systolic blood pressure of 130 mm Hg or greater; had a potassium level of less than 4.8 mmol/L; had a sodium level greater than 135 mmol/L; had an estimated glomerular filtration rate (eGFR) greater than 45 mL/min/1.73 m 2 ; and had less than a 25% reduction in eGFR from randomization. Of the 270 participants randomized to 50 mg of lorundrostat once daily, 92 (34.1%) were escalated to the 100-mg dose. c Included participants who received at least 1 dose of trial drug according to treatment assignment at randomization. d Included participants who received at least 1 dose of trial drug according to the actual treatment they received.
非 KM Figure
Figure 2Figure 2.. Changes in Office Blood Pressure From Randomization (Baseline) to Week 6 The box plots demonstrate the median (thick horizontal line), mean (circle), IQR (box top and bottom), and the maximum and minimum blood pressure (whiskers). The mean data were calculated using the last 4 of 5 blood pressure measurements at the baseline visit and at the week 6 visit.
非 KM Figure
Figure 3Figure 3.. Subgroup Analyses of Office Blood Pressure Changes From Randomization (Baseline) to Week 6 a The data for lorundrostat were pooled (n = 808) and included the 538 participants from the 50-mg only group plus the 270 participants in the 50-mg dose group with the 100-mg escalation option. b Included the categories of American Indian or Alaska Native, Asian, and Native Hawaiian or Other Pacific Islander. c Calculated as weight in kilograms divided by height in meters squared.
非 KM Figure